semaglutide products FDA crackdown on off-brand Ozempic set to take effect, threatening supply and access for many Obesity | Novo Nordisk U.S.

Hydrating properly

Studies have demonstrated that transitioning between GLP-1 receptor agonists is generally well-tolerated when conducted appropriately, with patients able to maintain therapeutic benefits throughout the transition process

Among 173 RA patients with overweight or obesity who were prescribed GLP-1 agonists and actually took them, 32% showed improvement in RA disease activity after 1 year, compared with 17% of 42 patients who were also prescribed the drugs but never started them, according to Veena Ranganath, MD, MS, of the University of California Los Angeles (UCLA), and colleagues

Special Diet Services Ltd., Witham, Essex, UK)

Data from a Phase 2a sub-study revealed a remarkable reduction in liver fat